2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P11235
    Berobenatide 3028974-74-2 98%
    Berobenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist.
    Berobenatide
  • HY-P1123R
    MEDICA16 (Standard) 87272-20-6
    Tacrine (hydrochloride) (Standard) is the analytical standard of Tacrine (hydrochloride). This product is intended for research and analytical applications. Tacrine hydrochloride is a potent inhibitor of both AChE and BChE, with IC50s of 31 nM and 25.6 nM, respectively. Tacrine hydrochloride is also a NMDAR inhibitor, with an IC50 of 26 μM. Tacrine hydrochloride can be used for the research of Alzheimer’s disease.
    MEDICA16 (Standard)
  • HY-P11245
    NN1213 98%
    NN1213, a long-acting human amylin peptide analog, is a selective Amylin receptor agonist with EC50 values of 0.177 and 0.262 nM for hAMY3R and rAMY3R, respectively. NN1213 significantly reduces food intake and fat mass. NN1213 can reduce body weightin diet-induced obese rats. NN1213 can be used for the research of obesity.
    NN1213
  • HY-P11246
    A13:B7-24-GG 3057097-31-8
    A13:B7-24-GG is an engineered analogue of insulin-like peptide 5 (INSL5), a selective RXFP4 agonist with a Ki value of 2.29 nM. A13:B7-24-GG has an extremely low binding affinity for RXFP3 (Ki = 602.56 nM) and an inhibitory effect on cAMP (EC50) of 1.17 nM. Activation of RXFP4 by A13:B7-24-GG leads to the recruitment of β-Arrestin2, with an EC50 of 22.39 nM. A13:B7-24-GG can be used for research on chronic constipation.
    A13:B7-24-GG
  • HY-P11258
    UPG-108 3090686-88-4
    UPG-108, a peptide compound, is a non-competitive allosteric modulator of Urotensin II receptors (UTR). UPG-108 significantly enhances the efficacy of UTR agonists but reduces the potency of UTR agonists. UPG-111 efficiently induces calcium release and does not cause contraction of rat aortic rings without endothelial denudation. UPG-111 can be used to study various diseases related to the angiotensinergic system.
    UPG-108
  • HY-P11259
    UPG-111 3090687-02-5
    UPG-111 is a peptide compound that acts as a negative allosteric modulator of the Urotensin II receptor (UTR). UPG-111 exhibits a dual inhibitory effect on the vasoconstriction induced by UTR agonists - it reduces both the maximum response intensity and the sensitivity of the agonist. UPG-111 does not induce calcium release or cause contraction of the endothelium-deprived rat aortic rings. UPG-111 can be used for the study of various diseases related to the angiotensinergic system.
    UPG-111
  • HY-P11260
    MD5 3051556-89-6 98%
    MD5 is a selective TMPRSS6 mimetic peptide inhibitor with an IC50 for recombinant human TMPRSS6 protein of 22 nM and a Ki of 3.4 nM. MD5 exhibits the significantly reduced inhibitory effect on Matriptase, with an IC50 of 352 nM and a Ki of 99.2 nM. MD5 exhibits good target specificity and only has a weak inhibitory effect on thrombin (Thrombin), with Ki of 120 nM. MD5 demonstrates good initial drugability and can be used for the study of iron overload diseases (such as hereditary hemochromatosis, β-thalassemia).
    MD5
  • HY-P11262
    GUB021794
    GUB021794 is a potent and highly selective glucagon-like peptide-1 receptor (GLP-1R) agonist developed using the streaMLine platform with an EC50 value of 18 pM. GUB021794 has a very weak activity against SCTR, with an EC50 value of 190 nM. GUB021794 can significantly reduce the body weight, food intake, and total fat mass of mice in a diet-induced obesity (DIO) model. GUB021794 can be used for research on obesity/diabetes.
    GUB021794
  • HY-P11264
    Cyclic peptide P1-1 98%
    Cyclic peptide P1-1 is a high-potent GPR55 antagonist. Cyclic peptide P1-1 antagonizes GPR55 and suppresses collagen secretion. Cyclic peptide P1-1 reduces ROS production, attenuates ER stress, and inhibits mitochondria-associated Apoptosis. Cyclic peptide P1-1 inhibits the expression of α-SMA and COL1α. Cyclic peptide P1-1 ameliorates CCl4 (HY-Y0298)-induce and MCD-diet-induce acute liver inflammation and fibrosis.
    Cyclic peptide P1-1
  • HY-P11269
    Lenbelintide 2793341-99-6 98%
    Lenbelintide is a dual amylin/calcitonin receptor agonist. Lenbelintide can be studied in research on obesity.
    Lenbelintide
  • HY-P11270
    Relsipatide 2843676-09-3 98%
    Relsipatide (BG128) is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Enicepatide can be studied in antidiabetic research.
    Relsipatide
  • HY-P11275
    TC4 98%
    TC4 is a highly balanced single-molecule quadruple agonist that can respectively activate GIPR, GLP-1R, GcgR, and Y2R with IC50 values of 0.95, 31, 81, and 1100 nM respectively. TC4 exhibits extremely strong signal bias on GLP-1R and has very low recruitment efficacy for β-inhibitor protein 2 (βArr2) and this strong cAMP preference is believed to maximize metabolic benefits (such as weight loss and hypoglycemia) while possibly minimizing side effects mediated by β-inhibitor protein recruitment (such as receptor desensitization). TC4 can be used for research on obesity and diabetes.
    TC4
  • HY-P11279
    TC2 98%
    TC2 is an efficient GIPR-preferring monomeric quadruple agonist that can respectively activate GIPR, GLP-1R, GcgR, and Y2R with IC50 values of 0.47, 2.1, 30, and 55 nM respectively. TC2 exhibits a significant GLP-1R preference, with a significant reduction in β-inhibitory protein 2 (βArr2) recruitment, while maintaining a strong cAMP signal. TC2 can be used for research on obesity and diabetes.
    TC2
  • HY-P11285
    LAGIPRA peptide 98%
    LAGIPRA peptide is a long-acting GIP1R agonist. LAGIPRA peptide enhances insulin sensitivity by augmenting glucose disposal and reduces branched-chain amino acids (BCAAs) and ketoacids. LAGIPRA peptide has the potential for the research of type 2 diabetes.
    LAGIPRA peptide
  • HY-P1128A
    Galanin (swine) TFA 98%
    Galanin (swine) TFA, a neuropeptide, consists of 29 amino acids and contains a C-terminal amidated glycine. Galanin (swine) inhibits basal and stimulated insulin secretion both in vivo and in vitro under a variety of experimental conditions. Galanin (swine) TFA is a galanin receptor agonist with pKis of 9.63, 9.49, 9.02, 8.98, 8.01 and 8.14 at human GAL1, rat GAL1, human GAL2, rat GAL2, human GAL3 and rat GAL3 respectively.
    Galanin (swine) TFA
  • HY-P11321
    IUB0271
    IUB0271 (acyl-GIP) is a fatty acylated and long-acting glucose-dependent insulinotropic polypeptide (GIP). IUB0271 increases cFos neuronal activity in hypothalamic feeding centers and decreases body weight, food intake and glycemia in DIO mouse models, and these effects depend on CNS-GIPR signaling. IUB0271 can be used for type 2 diabetes mellitus (T2DM) and obesity research.
    IUB0271
  • HY-P11361
    Des B30 Insulin
    Des B30 Insulin is a bioactive insulin analogue lacking the B30 amino acid residue. Des B30 Insulin can be used for the study of diabetes.
    Des B30 Insulin
  • HY-P11367
    Boc-Ala-Gly-Pro-Arg-AMC 118850-78-5
    Boc-Ala-Gly-Pro-Arg-AMC is a synthetic fluorescent substrate, widely used for the detection of protease activity. Boc-Ala-Gly-Pro-Arg-AMC can be used to detect the activity of serine proteases and the oligopeptide enzyme B of Trypanosoma brucei.
    Boc-Ala-Gly-Pro-Arg-AMC
  • HY-P11380
    Capa-2 454186-80-2 98%
    Capa-2 is a neuropeptide. Capa-2 activates calcium ion influx, stimulates the production of NO, activates soluble guanylate cyclase (sGC), increases intracellular cGMP, and drives ion and fluid secretion. Capa-2 can be used in studies of diuresis.
    Capa-2
  • HY-P11429
    [Asp5,6,Me-Phe8] Substance P (5-11) 98%
    [Asp5,6,Me-Phe8] Substance P (5-11) is a tachykinin NK-3 receptor agonist. [Asp5,6,Me-Phe8] Substance P (5-11) reduces alcohol intake in genetically selected alcohol-preferring rats.
    [Asp5,6,Me-Phe8] Substance P (5-11)
Cat. No. Product Name / Synonyms Application Reactivity